Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology

SIMPLE SUMMARY: About 20% of patients with cancer who participate in a phase I clinical trial discontinue the trial early. Early trial discontinuation is undesirable both for the wellbeing of the patient as well as for the trial efficiency and the development of new anticancer drugs. We investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Douma, Joeri A. J., Buffart, Laurien M., Sedhom, Ramy, Labots, Mariette, Menke-van der Houven van Oordt, Willemien C., Skardhamar, Mikkjal, De Felice, Anthony, Lee, Esther, Dharmaraj, Divya, Azad, Nilofer S., Carducci, Michael A., Verheul, Henk M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151105/
https://www.ncbi.nlm.nih.gov/pubmed/34064995
http://dx.doi.org/10.3390/cancers13102304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151105/
https://www.ncbi.nlm.nih.gov/pubmed/34064995
http://dx.doi.org/10.3390/cancers13102304

Ejemplares similares